CDx Diagnostics launches new version of OralCDx

CDx Diagnostics is launching an enhanced, second-generation version of its OralCDx test for detecting oral precancer and cancer at the annual scientific meetings of the American Academy of Otolaryngology -- Head and Neck Surgery and the American Association of Oral and Maxillofacial Surgeons, both being held this week.

p>The enhanced test, branded as OralCDx2, is the result of clinical experience with more than 500,000 computer-assisted OralCDx oral brush biopsies, 10 years of correlative experience with matching scalpel biopsies, and the inclusion of biomarkers, cell cycle analysis, and human papillomavirus (HPV) testing, all of which is correlated with the presence of abnormal cellular morphology, according to the company.

The central benefit of OralCDx2 is an increase in the proportion of oral lesions for which a specific diagnosis can be made to 98% of all cases, CDx claims.

In addition to providing a definitive laboratory report, OralCDx2 abnormal findings are accompanied with a telephonic consultation from the laboratory that provides specific follow-up and prognostic guidance based on the combination of morphologic and molecular findings.

CDx Diagnostics is upgrading all existing OralCDx test kits to OralCDx2 test kits at no charge.